Search Results

INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.

INVO Bioscience, Inc. announced financial results for the first quarter of 2024 and provided a business update.

INVO and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024.

INVO Bioscience, Inc. and NAYA Biosciences Inc. today jointly announced that they have entered into a definitive merger agreement (the “Merger”) for INVO to acquire NAYA Biosciences in an all-stock transaction.

INVO Bioscience, Inc. today announced the Company received notice from The Nasdaq Capital Market, LLC (“Nasdaq”), dated November 22, 2023, informing INVO that it has regained compliance with the minimum stockholders’ equity requirement as set forth under NASDAQ Listing Rule 5550(b)(1) for continued listing on Nasdaq.

INVO Bioscience, Inc. and NAYA Biosciences Inc. jointly announced that following the closing of their pending merger, Dr. Peter Kash, Ed.D., MBA will join the combined company’s Board of Directors as Vice Chairman.

INVO Bioscience, Inc. announced that it is soliciting waivers from holders of the Company’s common stock purchase warrants dated August 8, 2023 of the holder’s right to exercise a cash payment option upon consummation of the previously announced proposed merger with NAYA Biosciences, Inc., a Delaware corporation.

INVO Bioscience, Inc. announced financial results for the third quarter ended September 30, 2023 and provided a business update.

INVO Bioscience, Inc. announced that its special meeting of shareholders on September 29, 2023 was convened and then adjourned, without conducting any business, in order to provide shareholders additional time within which to vote on the proposals as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on September 1, 2023.